Ciprofibrate
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| |
| Ciprofibrate
| |
| Systematic (IUPAC) name | |
| 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2- methylpropanoic acid | |
| Identifiers | |
| CAS number | |
| ATC code | C10 |
| PubChem | |
| Chemical data | |
| Formula | C13H14Cl2O3 |
| Mol. mass | 289.154 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
|
WikiDoc Resources for Ciprofibrate | |
|
Articles | |
|---|---|
|
Most recent articles on Ciprofibrate Most cited articles on Ciprofibrate | |
|
Media | |
|
Powerpoint slides on Ciprofibrate | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Ciprofibrate at Clinical Trials.gov Clinical Trials on Ciprofibrate at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Ciprofibrate
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on Ciprofibrate Discussion groups on Ciprofibrate Patient Handouts on Ciprofibrate Directions to Hospitals Treating Ciprofibrate Risk calculators and risk factors for Ciprofibrate
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Ciprofibrate | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Businness | |
|
Experimental / Informatics | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-525-6884
Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Ciprofibrate is a fibrate.
Lipid modifying agents (C10) | |
|---|---|
| Statins | Atorvastatin • Cerivastatin‡ • Fluvastatin • Lovastatin • Mevastatin • Pitavastatin • Pravastatin • Rosuvastatin • Simvastatin |
| Fibrates | Clofibrate‡ • Bezafibrate • Aluminium clofibrate • Gemfibrozil • Fenofibrate • Simfibrate • Ronifibrate • Ciprofibrate • Etofibrate • Clofibride |
| Bile acid sequestrants | Colestyramine • Colestipol • Colestilan • Colextran • Colesevelam |
| Niacin and derivatives | Niceritrol • Niacin • Nicofuranose• Aluminium nicotinate• Nicotinyl alcohol • Acipimox |
| CETP inhibitors | Anacetrapib† • Torcetrapib§ |
| Combinations | Niacin/lovastatin • Niacin/simvastatin • Ezetimibe/simvastatin |
| Other | Dextrothyroxine • Probucol • Tiadenol • Benfluorex • Meglutol • Omega-3-triglycerides • Magnesium pyridoxal 5-phosphate glutamate • Policosanol • Ezetimibe • Laropiprant • Lapaquistat§ |
| †Undergoing clinical trials. ‡Withdrawn from market. §Development terminated. | |
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
